Subhash Thuluva

Dr. Subhash Thuluva

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2022 in EBioMedicine
Verified
Journal Article
Open access
STSubhash Thuluva
Subhash Thuluva
VPVikram Paradkar
Vikram Paradkar
SGSubba Reddy Gunneri
Subba Reddy Gunneri
VYVijay Yerroju
Vijay Yerroju
RMRammohan Reddy Mogulla
Rammohan Reddy Mogulla
VAVenkateshwar Rao A
Venkateshwar Rao A
We assessed the efficacy of a receptor-binding domain (RBD)-based protein subunit COVID-19 vaccine. A randomised Phase-1/2 trial followed by a Phase-2 trial were conducted to assess the safety and immunogenicity of the COVID-19 vaccine Corbevax and select to an optimum formulation. Healthy adults (n=460) without COVID-19 vaccination or SARS-CoV-2 infection in the Phase-1/2 study were randomly divided into four vaccine formulation groups. A low incidence of adverse events was reported post-vaccination. All formulations showed similar profiles of humoral and cellular immune responses that were associated with the content of CpG1018 adjuvant in the vaccine. In the Phase-2 study, 750 µg of CpG1018 showed significant improvement (> 4-fold increase from baseline) in immune responses, including the titres of anti-RBD IgG and neutralising antibody (nAb), and cellular immune responses, while maintaining the safety profile. Antibodies persisted consistently for 12 months after the second dose of vaccine. Corbevax (two-dose schedule with 28 days of interval between doses) was well tolerated with no observed safety concerns. Previous observations from efficacy studies by Moderna and AstraZeneca and the correlation between nAb titres post-vaccination and a human convalescent serum panel showed that Corbevax induced significantly high nAb titres. These studies were prospectively registered with the Clinical Trial Registry of India (CTRI/2021/06/034014 and CTRI/2020/11/029032). Bill & Melinda Gates Foundation, BIRAC-Division of Department of Biotechnology, Govt of India, and the Coalition for Epidemic Preparedness Innovations funded this study.

2 January 2023 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
STSubhash Thuluva
Subhash Thuluva
VPVikram Paradkar
Vikram Paradkar
SGSubbaReddy Gunneri
SubbaReddy Gunneri
VYVijay Yerroju
Vijay Yerroju
RMRammohan Mogulla
Rammohan Mogulla
APAnil Kumar Pandey
Anil Kumar Pandey
Optimum formulation of Biological-E’s protein subunit CORBEVAX™ vaccine was selected in phase-1 and -2 studies and found to be safe and immunogenic in healthy adult population. This is a phase-3 prospective, single-blinded, randomized, active controlled study conducted at 18 sites across India in 18–80 year-old subjects. This study has two groups; (i) immunogenicity-group, participants randomized either to CORBEVAX™ (n = 319) or COVISHIELD™ arms (n = 320). (ii) Safety-group containing single CORBEVAX™ arm (n = 1500) and randomization is not applicable. Healthy adults without a history of COVID-19 vaccination or SARS-CoV-2 infection were enrolled into immunogenicity arm and subjects seronegative to SARS-CoV-2 infection were enrolled into the safety arm. The safety profile of CORBEVAX™ vaccine was comparable to the comparator vaccine COVISHIELD™. Majority of reported AEs were mild in nature in both arms. The CORBEVAX™ to COVISHIELD™ GMT-ratios at day-42 time-point were 1·15 and 1·56 and the lower limit of the 95% confidence interval for the GMT-ratios was determined as 1·02 and 1·27 against Ancestral and Delta strains of SARS-COV-2 respectively. Both COVISHIELD™ and CORBEVAX™ vaccines showed comparable seroconversion post-vaccination against anti-RBD-IgG response. The subjects in CORBEVAX™ cohort also exhibited higher interferon-gamma secreting PBMC’s post-stimulation with SARS-COV-2 RBD-peptides than subjects in COVISHIELD™ cohort.

25 March 2022 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
STSubhash Thuluva
Subhash Thuluva
VPVikram Paradkar
Vikram Paradkar
RMRamesh Matur
Ramesh Matur
KTKishore Turaga
Kishore Turaga
SGSubba Reddy Gv
Subba Reddy Gv
The current scenario of typhoid fever warrants early prevention with typhoid conjugate vaccines in susceptible populations to provide lifelong protection. We conducted a multicenter, single-blind, randomized, Phase 2/3 study to assess the immunogenicity and safety of Biological E’s Typhoid Vi-CRM197 conjugate vaccine (TyphiBEVTM) compared to Vi-TT conjugate vaccine manufactured by Bharat Biotech International Limited (Typbar-TCV; licensed comparator) in healthy infants, children, and adults from India. The study’s primary objective was to assess the non-inferiority of TyphiBEVTM in terms of the difference in the proportion of subjects seroconverted with a seroconversion threshold value of ≥2.0 µg/mL against Typbar-TCV. A total of 622 healthy subjects (311 each in both vaccine groups) were randomized and received the single dose of the study vaccine. The TyphiBEVTM group demonstrated noninferiority compared to the Typbar-TCV group at Day 42. The lower 2-sided 95% confidence interval limit of the group difference was −.34%, which met the non-inferiority criteria of ≥10.0%. The geometric mean concentration (24.79 µg/mL vs. 26.58 µg/mL) and proportion of subjects who achieved ≥4-fold increase in antiVi IgG antibody concentrations (96.95% vs. 97.64%) at Day 42 were comparable between the TyphiBEVTM and Typbar-TCV vaccine groups. No apparent difference was observed in the safety profile between both vaccine groups. All adverse events reported were mild or moderate in intensity in all age subsets. This data demonstrates that TyphiBEVTM is non-inferior to TypbarTCV in terms of immunogenicity, and the overall safety and reactogenicity in healthy infants, children, and adults studied from India was comparable.

31 October 2022 in Vaccine
Verified
Journal Article
Closed access
STSubhash Thuluva
Subhash Thuluva
VPVikram Paradkar
Vikram Paradkar
SGSubbaReddy Gunneri
SubbaReddy Gunneri
VYVijay Yerroju
Vijay Yerroju
RMRammohan Reddy Mogulla
Rammohan Reddy Mogulla
APAnil Kumar Pandey
Anil Kumar Pandey

17 April 2024 in Vaccine
Verified
Journal Article
Closed access
RMRamesh V. Matur
Ramesh V. Matur
STSubhash Thuluva
Subhash Thuluva
SGSubbareddy Gunneri
Subbareddy Gunneri
VYVijay Yerroju
Vijay Yerroju
RMRammohan Reddy Mogulla
Rammohan Reddy Mogulla
JNJai Prakash Narayan
Jai Prakash Narayan

22 March 2022 in medRxiv
Verified
Preprint
Open access
PDF file
STSubhash Thuluva
Subhash Thuluva
VPVikram Paradkar
Vikram Paradkar
KTKishore Turaga
Kishore Turaga
SGSubbareddy Gunneri
Subbareddy Gunneri
VYVijay Yerroju
Vijay Yerroju
PSPv Suneetha
Pv Suneetha
Background Optimum formulation of Biological E’s CORBEVAX™ vaccine that contains protein sub unit of Receptor Binding Domain (RBD) from the spike protein of SARS-COV-2 formulated with aluminum hydroxide (Al3+) and CpG1018 as adjuvants was selected in phase-1 and 2 studies and proven to be safe, well tolerated and immunogenic in healthy adult population. In the current study, additional data was generated to determine immunogenic superiority of CORBEVAX™ vaccine over COVISHIELD™ vaccine and safety in larger and older population. Methods This is a phase III prospective, single blinded, randomized, active controlled study (CTRI/2021/08/036074) conducted at 20 sites across India in healthy adults aged between 18-80 years. This study has two arms; immunogenicity arm and safety arm. Participants in immunogenicity arm were randomized equally to either CORBEVAX™™ or COVISHIELD™ vaccination groups to determine the immunogenic superiority. Healthy adults without a history of Covid-19 vaccination or SARS-CoV-2 infection, were enrolled. Findings The safety profile of CORBEVAX™ vaccine was comparable to the comparator vaccine COVISHIELD™ in terms of overall AE rates, related AE rates and medically attended AEs. Majority of reported AEs were mild in nature, and overall CORBEVAX™ appeared to cause fewer local and systemic adverse reactions/events. Overall, two grade-3 serious AEs (Dengue fever and femur fracture) were reported and they are unrelated to study vaccine. Neutralizing Antibody titers, against both Ancestral and Delta strain, induced post two-dose vaccination regimen were higher in the CORBEVAX™ arm as compared to COVISHIELD™ and the analysis of GMT ratios demonstrated immunogenic superiority of CORBEVAX™ in comparison with COVISHIELD™. Both CORBEVAX™ and COVISHIELD™ vaccines showed comparable seroconversion post vaccination when assessed against anti-RBD IgG response. The subjects in CORBEVAX™ cohort also exhibited higher Interferon-gamma secreting PBMC’s post stimulation with SARS-COV-2 RBD peptides than the subjects in COVISHIELD™ cohort. Interpretations Neutralizing antibody titers induced by CORBEVAX™ vaccine against Delta and Ancestral strains were protective, indicative of vaccine effectiveness of >90% for prevention of symptomatic infections based on the Correlates of Protection assessment performed during Moderna and Astra-Zeneca vaccine Phase III studies. Safety findings revealed that CORBEVAX™ vaccine has excellent safety profile when tested in larger and older population. Funding BIRAC-division of Department of Biotechnology, Government of India, and the Coalition for Epidemic Preparedness Innovations funded the study.